サンプル依頼リスト カート
  • English
  • Korean
表紙：胃がん治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1345463

胃がん治療の世界市場-2023年～2030年

Global Stomach Cancer Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
胃がん治療の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

胃がん治療の世界市場は、2022年に47億米ドルに達し、2023～2030年の予測期間中にCAGR 8.7％で成長し、2030年には103億米ドルに達すると予測されます。

胃がんは、胃の粘膜に悪性（がん）細胞ができる病気です。胃がんは通常、胃を覆う粘液産生細胞から始まります。胃がんの症状には、消化不良や胃の不快感、痛みなどがあります。ほとんどの人は初期の段階では徴候を示さないのが普通で、そのため診断が難しくなります。このため、胃がんは他の体の部位に転移して転移を起こすまで診断されないことが多いです。

胃がんは世界中で死因の第3位を占めています。米国国立がん研究所によると、がんによる死亡者の1.8％が胃がんによるものです。米国がん学会の2022年の推計によると、胃がんは毎年米国で新たに発生するがんの約1.5％を占めています。

さらに、胃がんの罹患率の上昇、座りがちなライフスタイルや不規則な食習慣の採用、腫瘍学分野における研究開発の高まりは、今後一定期間の市場を牽引すると予想されるいくつかの要因です。

ダイナミクス

製品上市の増加

胃がんは現在、世界で5番目に多く診断されるがんであり、がん関連死因の第4位を占めています。症例の90～95％以上が腺がんに分類されます。米国がん協会の2022年の推定では、胃がんによる新規症例は26,380例、死亡は11,090例となっています。

例えば、2023年2月、Enhertu社は韓国で胃がん3次治療を開始しました。最初で唯一のHER2標的ADCで、進行・転移性胃がんの治療を改善します。

さらに、2023年4月、HUTCHMED（China）Limitedは、パクリタキセルとともに進行性胃がんまたは胃食道接合部腺がんの二次治療を適応とするフルキンチニブの新薬承認申請（「NDA」）を中国国家医薬品監督管理局（「NMPA」）に受理されました。

医薬品パイプラインの増加

様々なバイオテクノロジー企業や製薬企業が、パイプラインにある様々な医薬品を開発しています。CNBG-Virogin Biotech、Minneamrita Therapeutics LLCなどです。これらの薬剤は胃がんの治療における安全性と有効性が試験されています。治療効果を観察するために、併用薬が患者に投与されます。

浙江省がん病院はCSPC Ouyi Pharmaceutical Co., Ltd.と共に、ステージ3の胃がんに対する術後補助療法として、アルブミン結合パクリタキセル＋S-1とオキサリプラチン＋カペシタビン（XELOX）の有効性と安全性を比較する第3相臨床試験を実施しています。終了予定日は2024年10月31日です。

放射線療法と化学療法に関連する合併症

化学療法と放射線療法は胃がんの主要な治療法です。化学療法はまた、日光過敏症や日焼けのリスクの増加などの影響をもたらす可能性があります。化学療法によって一時的に乳糖不耐症になることもあります。胃がんに対する化学療法と放射線療法はともに、下痢、吐き気、嘔吐を引き起こすことがあります。骨盤に放射線を照射したり、化学療法薬の中には尿路感染症（UTI）を引き起こすものもあります。胃がんの治療とは別に、エストロゲンレベルを低下させ、膣乾燥症などの症状や原発性卵巣機能不全、テストステロンレベル、精子数などの状態を引き起こすことがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品上市の増加
      • 医薬品パイプラインの増加
    • 抑制要因
      • 放射線療法と化学療法に関連する合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 がんタイプ別

  • 腺がん
  • 消化管間質腫瘍（GIST）
  • カルチノイド腫瘍
  • リンパ腫
  • その他

第8章 治療タイプ別

  • 外科治療
    • 内視鏡的粘膜切除術
    • 胃切除術
    • 内腔ステント留置術
    • 内腔レーザー治療
    • 胃噴門形成術
  • 放射線療法
  • 化学療法
    • カペシタビン
    • シスプラチン
    • ドセタキセル
    • オキサリプラチン
    • パクリタキセル
    • その他
  • 標的療法
    • ラムシルマブ
    • レゴラフェニブ
    • トラスツズマブ
    • その他
  • 免疫療法
    • ニボルマブ
    • ペムブロリズマブ
    • 温熱腹腔内化学療法（HIPEC）
    • その他
  • その他

第9章 販売チャネル別

  • 病院・クリニック
  • がん治療センター
  • がん研究機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Merck & Co.
    • 企業概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な動向
  • Bristol-Myers Squibb
  • Accord Healthcare
  • Sanofi S.A.
  • Bayer Pharma AG
  • Eli Lilly and Company
  • Teva Pharmaceuticals Industries, Ltd.
  • Celltrion, Inc.
  • Genentech, Inc.
  • Winthrop US

第13章 付録

目次
Product Code: PH2190

Overview

Global Stomach Cancer Treatment Market reached US$ 4.7 billion in 2022 and is expected to reach US$ 10.3 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.

Stomach cancer is a disease in which malignant (cancer) cells are formed in the stomach lining. Stomach cancer usually begins in the mucus-producing cells that line the stomach. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. Most people typically do not show signs in the earlier stages due to which diagnosis becomes difficult. Because of this, it often goes undiagnosed until after it spreads to other body parts and cause metastasis.

Gastric cancer is the third leading cause of death throughout the world. According to the National Cancer Institute, 1.8% of the deaths caused by cancer are due to stomach cancer. According to the American Cancer Society estimate in 2022, stomach cancer accounts for about 1.5% of all new cancers in the U.S. annually.

Furthermore, the rising incidence of gastric cancer, the adoption of a sedentary lifestyle and irregular food habits, and rising research and development in the oncology sector are a few factors that are expected to drive the market in the forthcoming period.

Dynamics

Increasing Product Launches

Gastric cancer is currently the fifth most frequently diagnosed cancer and the fourth leading cancer-related cause of death worldwide. Over 90-95% of cases are classified as adenocarcinoma. The American Cancer Society's 2022 estimates include 26,380 new cases and 11,090 deaths from gastric cancer.

For instance, in February 2023, Enhertu launched gastric cancer tertiary treatment in South Korea. The first and only HER2 target ADC, which improves treatment for advanced and metastatic gastric cancer.

Additionally, in April 2023, HUTCHMED (China) Limited was granted a New Drug Application ("NDA") for fruquintinib along with paclitaxel for the treatment of second-line progressive gastric or gastroesophageal junction adenocarcinoma in China was accepted for consideration by the China National Medical Products Administration ("NMPA").

Increasing Drug Pipeline

Various biotech and pharmaceutical companies are developing various drugs which are in the pipeline. Companies like CNBG-Virogin Biotech, Minneamrita Therapeutics LLC, etc. These drugs are tested for safety and efficacy in treating gastric cancer. Combination drugs are given to the patients to observe the effectiveness of the therapy.

Zhejiang Cancer Hospital along with CSPC Ouyi Pharmaceutical Co., Ltd. are conducting a phase 3 clinical trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage 3 gastric cancer as adjuvant setting. The estimated completion date is October 31, 2024.

Complications Related to Radiotherapy and Chemotherapy

Chemotherapy and radiotherapy are the leading treatments for stomach cancer. Chemotherapy may also lead to implications such as sunlight sensitivity and increasing sunburn risk. Chemotherapy can cause individuals to become temporarily lactose intolerant. Both chemotherapy and radiation therapy for stomach cancer can cause diarrhea, nausea, and vomiting. Radiation toward the pelvis and some chemotherapy drugs lead to urinary tract infections (UTIs). Apart from treating stomach cancer, it can decrease estrogen levels, causing symptoms like vaginal dryness and conditions like primary ovarian insufficiency, testosterone levels, and sperm count.

Segment Analysis

The global stomach cancer treatment market is segmented based on cancer type, treatment type, end-user, and region.

Chemotherapy can target cancer cells that have spread beyond the stomach or shrink the tumor before surgery and alleviate symptoms in advanced cases of gastric cancer. The use of chemotherapy in gastric cancer is rapidly evolving, and the optimal treatment strategy may vary depending on the tumor's molecular characteristics, the stage of cancer, and other individual factors.

Due to the increased use of chemotherapy treatment for stomach cancer, there is an increase in chemotherapeutic products in the market. For instance, in April 2022, BDR Pharmaceuticals launched Furmecil, a generic oral drug for treating advanced gastric cancer.

Furthermore, in June 2023, Merck & Co.'s Keytruda, in a new phase 3 trial, Keytruda plus chemotherapy, significantly extended patients' lives over chemo alone in newly diagnosed HER2-negative gastric or gastroesophageal junction cancers that are advanced or metastatic. The Keytruda combination cut the risk of death by 22%.

Geographical Analysis

North America accounts for the largest market share for stomach cancer treatment. The American Cancer Society's estimates for stomach cancer (also known as gastric cancer) in the United States for 2023 are about 26,500 new cases of stomach cancer (15,930 in men and 10,570 in women).

In addition to that, lifestyle factors such as improper diet and smoking cause gastric cancer. Diets high in salt, smoked or pickled foods, and low in fruits and vegetables have been linked to an increase in the risk of gastric cancer. Similarly, smoking is a most common risk factor for gastric cancer and the prevalence of smoking in many countries in North America remains high. All these factors are anticipated to boost the growth of the North American gastric cancer market during the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has also had a massive impact on secondary care. Hospitals and health centers reduced their functioning capacity to maintain social distancing measures by government guidelines, which consequently delayed cancer diagnosis. A March 2021 report noted a 60% decrease in new oncology clinical trials during the pandemic, fueling concerns regarding slowing the development of new cancer therapies. A major UK-based cancer research charity, Cancer Research UK, halted recruitment in 95% of their clinical trials to protect cancer patients including stomach cancer, and cope with the redeployment of clinical research staff to support frontline COVID-19-facing healthcare services.

By Type

  • Adenocarcinoma
  • Gastrointestinal stromal tumors (GIST)
  • Carcinoid tumors
  • Lymphoma
  • Others

By Treatment Type

  • Surgery
    • Endoscopic mucosal resection
    • Gastrectomy
  • Subtotal
  • Total
    • Endoluminal stent placement
    • Endoluminal laser therapy
    • Gastrojejunostomy
  • Radiation therapy
  • Chemotherapy
    • Capecitabine
    • Cisplatin
    • Docetaxel
    • Oxaliplatin
    • Paclitaxel
    • Hyperthermic intraperitoneal chemotherapy (HIPEC)
    • Others
  • Targeted therapy
    • Ramucirumab
    • Regorafenib
    • Trastuzumab
  • Immunotherapy
    • Nivolumab
    • Pembrolizumab
  • Others

By Distribution Channel

  • Hospitals and Clinics
  • Cancer Centers
  • Cancer Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb signed an outsourcing agreement with Prime Research Institute for Medical RWD, Inc. Kyoto, Japan, an industry-sponsored, large-scale, multi-institutional clinical research in patients with gastric cancer treated with Opdivo in combination with chemotherapy.
  • In February 2023, AstraZeneca signed a global exclusive license agreement deal with KYM Biosciences, a joint venture established by affiliates of Keymed Biosciences and Lepu Biopharma. The deal is centered around CMG901, an antibody-drug conjugate (ADC) currently being evaluated as a potential treatment for gastric cancer.
  • In November 2022, Organon, a global women's health company, declared the availability and distribution of ONTRUZANT, a biosimilar of Herceptin, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer.

Competitive Landscape

The major global players in the stomach cancer treatment market include: Merck & Co., Inc, Bristol-Myers Squibb, Accord Healthcare, Sanofi S.A, Bayer Pharma AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Celltrion, Inc., Genentech, Inc., and Winthrop US among others.

Why Purchase the Report?

  • To visualize the global stomach cancer treatment market segmentation based on cancer type, treatment type, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of stomach cancer treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global stomach cancer treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches
      • 4.1.1.2. Increasing Drug Pipeline
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Related to Radiotherapy and Chemotherapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Adenocarcinoma
  • 7.3. Gastrointestinal stromal tumors (GIST)
  • 7.4. Carcinoid tumors
  • 7.5. Lymphoma
  • 7.6. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Surgery
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Endoscopic mucosal resection
    • 8.2.4. Gastrectomy
    • 8.2.5. Endoluminal stent placement
    • 8.2.6. Endoluminal laser therapy
    • 8.2.7. Gastrojejunostomy
  • 8.3. Radiation therapy
  • 8.4. Chemotherapy
    • 8.4.1. Capecitabine
    • 8.4.2. Cisplatin
    • 8.4.3. Docetaxel
    • 8.4.4. Oxaliplatin
    • 8.4.5. Paclitaxel
    • 8.4.6. Others
  • 8.5. Targeted therapy
    • 8.5.1. Ramucirumab
    • 8.5.2. Regorafenib
    • 8.5.3. Trastuzumab
    • 8.5.4. Others
  • 8.6. Immunotherapy
    • 8.6.1. Nivolumab
    • 8.6.2. Pembrolizumab
    • 8.6.3. Hyperthermic intraperitoneal chemotherapy (HIPEC)
    • 8.6.4. Others
  • 8.7. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cancer Care Centers
  • 9.4. Cancer Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co.
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bristol-Myers Squibb
  • 12.3. Accord Healthcare
  • 12.4. Sanofi S.A.
  • 12.5. Bayer Pharma AG
  • 12.6. Eli Lilly and Company
  • 12.7. Teva Pharmaceuticals Industries, Ltd.
  • 12.8. Celltrion, Inc.
  • 12.9. Genentech, Inc.
  • 12.10. Winthrop US

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us